...
首页> 外文期刊>Hepatitis Monthly >MANAGEMENT OF HEPATITIS B VIRUS INFECTION IN LIVER TRANSPLANTATION SETTING THE RISING CONCERNS AND GROWING HOPES, REPORT FROM 10TH CONGRESS OF THE IRANIAN SOCIETY FOR ORGAN TRANSPLANTATION, 2011, SHIRAZ, IRAN
【24h】

MANAGEMENT OF HEPATITIS B VIRUS INFECTION IN LIVER TRANSPLANTATION SETTING THE RISING CONCERNS AND GROWING HOPES, REPORT FROM 10TH CONGRESS OF THE IRANIAN SOCIETY FOR ORGAN TRANSPLANTATION, 2011, SHIRAZ, IRAN

机译:肝移植中乙型肝炎病毒感染的管理引起人们的关注和希望的增长,来自伊朗器官移植协会第十次大会的报告,2011年,伊朗希拉兹

获取原文

摘要

Hepatitis B infection is the main cause of liver related mortality in many countries including Iran. Liver transplantation in cirrhosis due to HBV infection before 1990 was an absolute contraindication. Recurrent infection was a significant event in post liver transplant setting and resulted in increased risk of graft failure and death except successful transplanted individuals. Advances in antiviral prophylaxis have now made graft reinfection majority patients as a rare event. Graft and patient survival have been improved significantly during the past two decades, and consequences of transplantation for hepatitis B virus are now superior to those achieved for most other indications. This has encouraged many centers including the major liver transplantation center of Iran, in Shiraz, to provide liver transplantation to more patients with HBV related end stage liver disease. Management of these patients begins before transplantation along with special care after transplantation. There are some myths and doubts in the management of these patients and one should always balance the cost and efficiency. One of the major concerns is the high economic and social cost of recurrence and all possible efforts should be performed to avoid the ominous consequences of reinfection. Having a clear scientific grasp on the management of HBV cirrhosis before and after liver transplantation, options and protocols, and changing the concept which HBV infected are contraindicated ones for liver transplantation, and future hopes in increasing patients survival after liver transplantation using the new nucleosides analogues and availability of hepatitis B immunoglobulin in the transplantation setting. This scientific report paper outlines the insights communicated at the HBV and liver transplantation symposium during 10th Congress of the Iranian Society for Organ Transplantation, May 2011, Shiraz, Iran.
机译:乙型肝炎感染是包括伊朗在内的许多国家与肝脏有关的死亡率的主要原因。 1990年前因HBV感染而导致肝硬化的肝移植是绝对禁忌症。反复感染是肝移植后的重要事件,除了成功移植的个体外,导致移植失败和死亡的风险增加。现在,抗病毒预防的进展已使大多数患者发生移植物再感染成为罕见事件。在过去的二十年中,移植物和患者的存活率得到了显着改善,而乙型肝炎病毒的移植后果现已优于大多数其他适应症。这鼓励了许多中心,包括设在设拉子(Shiraz)的伊朗主要肝移植中心,为更多与HBV相关的终末期肝病患者提供肝移植。这些患者的治疗开始于移植前以及移植后的特殊护理。这些患者的治疗存在一些误解和疑问,应该始终在成本和效率之间取得平衡。主要关注之一是复发的高昂经济和社会成本,应尽一切可能的努力避免再次感染的不祥后果。对肝移植前后的HBV肝硬化的治疗方法,方案和规程有明确的科学了解,并改变了HBV感染是肝移植的禁忌症的概念,并且未来希望通过使用新的核苷类似物来提高肝移植后患者的生存率和乙型肝炎免疫球蛋白在移植中的可用性。该科学报告概述了在2011年5月于伊朗设拉子举行的伊朗器官移植学会第十届大会期间在HBV和肝移植研讨会上传达的见解。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号